DBV TechnologiesDBVT -4.17%31 Return-on-Tangible-Asset is -76.16% as of Mar. 2026. GuruFocus rates DBVT with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,412 Biotechnology companies, DBV Technologies ranks worse than 79.82% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. DBV Technologies's annualizedNet Income for the quarter that ended in Mar. 2026 was $-190.40 Mil. DBV Technologies's average total tangible assets for the quarter that ended in Mar. 2026 was $250.00 Mil. Therefore, DBV Technologies's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -76.16%.
The historical rank and industry rank for DBV Technologies's Return-on-Tangible-Asset or its related term are showing as below:
DBVT'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -103.59 Med: -60.1 Max: -33.31
Current: -103.59
During the past 13 years, DBV Technologies's highest Return-on-Tangible-Asset was -33.31%. The lowest was -103.59%. And the median was -60.10%.
DBVT's Return-on-Tangible-Asset is ranked worse than 79.82% of 1412
companies
in the Biotechnology industry
Industry Median: -35.475
vs DBVT: -103.59
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
DBV Technologies Return-on-Tangible-Asset Related Terms
DBV Technologies Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for DBV Technologies's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DBVT vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, DBV Technologies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DBV Technologies Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DBV Technologies's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where DBV Technologies's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -76.16% mean?
DBV Technologies (DBVT) has a Return-on-Tangible-Asset of -76.16% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on DBV Technologies and its competitors. According to the industry distribution chart, DBV Technologies ranks #1127 out of 1412 companies in the Biotechnology industry, placing it in the top 79.8%.
Is DBV Technologies' Return-on-Tangible-Asset too high?
DBV Technologies' current Return-on-Tangible-Asset is -76.16%. Based on the distribution chart, DBV Technologies ranks #1127 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DBV Technologies has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DBV Technologies' Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DBV Technologies ranks #1127 out of 1412 companies for Return-on-Tangible-Asset. This places DBV Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on DBV Technologies and its competitors. DBV Technologies's current Return-on-Tangible-Asset is -76.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DBV Technologies stock overvalued right now?
DBV Technologies (DBVT) has a current Return-on-Tangible-Asset of -76.16%. The current Return-on-Tangible-Asset is -76.16%. DBV Technologies' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For DBV Technologies (DBVT), the current Return-on-Tangible-Asset is -76.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
31GF Score
Get the complete analysis for DBVT
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DBVT has been successfully added to your 
